Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Astellas Unveils Strategies For China

This article was originally published in PharmAsia News

Executive Summary

Astellas, Japan's second largest pharmaceutical manufacturer, is convinced that China's healthcare reforms will provide great opportunities for all pharmaceutical producers. Even though the Chinese market is now dominated by European and American companies, Astellas China revealed it will increase local new drug R&D and expand its distribution networks. Although slated reforms encourage pharmaceutical firms to focus on rural areas and low-profit drugs, Astellas will focus on patent and prescription drugs because the company believes that rural residents will still choose high quality drugs to reduce total medical care expenses. In addition, the company plans to acquire local pharmaceutical firms, but will proceed cautiously with this long-term strategy. Astellas has posted 20 percent annual growth in China over the past two years, with the market contributing to about 47 percent of its Asian revenue in the first half of 2009. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel